Trials / Unknown
UnknownNCT04298320
A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
Phase Ib/IIa Study of SHR-1210 Combined With AIN457 for Patients With Late Stage MSS CRC Who Failed Second-line and Above Treatment
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Yanqiao Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase Ib/IIa, Open-label, Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in combination with AIN457 for patients with late stage MSS CRC who failed second-line and above treatment. The main purpose of this study is to evaluate the safety, tolerability and RD of SHR-1210 combination with AIN457 as a treatment of MSS CRC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1210 | SHR-1210 was administered 200mg iv every 2 weeks |
| DRUG | AIN 457 | AIN457 was administered 150mg or 300mg ih every 2 weeks |
Timeline
- Start date
- 2020-03-15
- Primary completion
- 2022-02-28
- Completion
- 2023-02-28
- First posted
- 2020-03-06
- Last updated
- 2020-03-16
Source: ClinicalTrials.gov record NCT04298320. Inclusion in this directory is not an endorsement.